These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7699886)

  • 21. Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas.
    Palumbo AP; Boccadoro M; Battaglio S; Corradini P; Tsichlis PN; Huebner K; Pileri A; Croce CM
    Cancer Res; 1990 Oct; 50(20):6478-82. PubMed ID: 2208106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant expression of the K-ras proto-oncogene in B-cell malignancies.
    Lee J; Talpaz M; Walters R; Gutterman JU; Blick M
    Hematol Pathol; 1988; 2(4):229-37. PubMed ID: 3075608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular biology in gastric cancer].
    Kikuchi K; Ueda M; Kitajima M
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2139-46. PubMed ID: 10635296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ontogeny of Ha-ras and c-myc mRNA levels in rabbit embryo and extraembryonic tissues by quantitative in situ hybridization.
    Martinoli MG; Lambert RD; Pothier F; Pelletier G
    Mol Reprod Dev; 1992 Jan; 31(1):1-8. PubMed ID: 1562321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ras oncogene mutation in multiple myeloma.
    Neri A; Murphy JP; Cro L; Ferrero D; Tarella C; Baldini L; Dalla-Favera R
    J Exp Med; 1989 Nov; 170(5):1715-25. PubMed ID: 2681517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The oncoprotein phenotype of plasma cells from patients with multiple myeloma.
    Brown RD; Pope B; Luo XF; Gibson J; Joshua D
    Leuk Lymphoma; 1994 Dec; 16(1-2):147-56. PubMed ID: 7696921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype.
    Pope B; Brown R; Luo XF; Gibson J; Joshua D
    Leuk Lymphoma; 1997 May; 25(5-6):545-54. PubMed ID: 9250826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular resistance mechanisms with impact on the therapy of multiple myeloma.
    Gieseler F; Nüssler V
    Leukemia; 1997 Dec; 11 Suppl 5():S1-4. PubMed ID: 9436930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular pathology of oncogenes and anti-oncogenes in diagnosis of colonic polyps].
    Monden T; Morimoto H; Nakanishi H; Fukunaga M; Shimano T; Mori T
    Nihon Rinsho; 1991 Dec; 49(12):88-96. PubMed ID: 1787590
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effects of
    Li RB; Pu JN; Li BR; Cai Y; Zhang ZH; Xu XY
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Nov; 39(11):825-830. PubMed ID: 34886641
    [No Abstract]   [Full Text] [Related]  

  • 31. Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.
    Hucthagowder V; Meyer R; Mullins C; Nagarajan R; DiPersio JF; Vij R; Tomasson MH; Kulkarni S
    Cancer Genet; 2012 Sep; 205(9):474-8. PubMed ID: 22939401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances Research on C-MYC Proto-oncogene in Multiple Myeloma -Review].
    Huang H; Guo WJ; Yao RX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1248-51. PubMed ID: 27531809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular resistance mechanisms with impact on the therapy of multiple myeloma.
    Gieseler F; Nüssler V
    Leukemia; 1998 Jul; 12(7):1009-12. PubMed ID: 9665183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology.
    Pileri A; Ferrero D; Massaia M; Dianzani U; Boccadoro M
    Eur J Haematol Suppl; 1989; 51():30-4. PubMed ID: 2697592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation.
    Pegoraro L; Malavasi F; Bellone G; Massaia M; Boccadoro M; Saglio G; Guerrasio A; Benetton G; Lombardi L; Coda R
    Blood; 1989 Mar; 73(4):1020-7. PubMed ID: 2784066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P53 deletion is not a frequent event in multiple myeloma.
    Avet-Loiseau H; Li JY; Godon C; Morineau N; Daviet A; Harousseau JL; Facon T; Bataille R
    Br J Haematol; 1999 Sep; 106(3):717-9. PubMed ID: 10468863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele.
    Ernst TJ; Gazdar A; Ritz J; Shipp MA
    Blood; 1988 Oct; 72(4):1163-7. PubMed ID: 3048435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detectability of immunoglobulin and c-myc gene rearrangements in multiple myeloma.
    Humphries JE; Williams ME
    Br J Haematol; 1993 Jan; 83(1):173-4. PubMed ID: 8435328
    [No Abstract]   [Full Text] [Related]  

  • 39. Genetic variants as biomarkers for progression and resistance in multiple myeloma.
    Montel RA; Gregory M; Chu T; Cottrell J; Bitasktsis C; Chang SL
    Cancer Genet; 2021 Apr; 252-253():1-5. PubMed ID: 33338886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk for cancer in multiple myeloma patients and their first-degree relatives.
    Varkonyi J; Kovalszky I; Nemeth A; Demeter J; Raposa T
    Haematologia (Budap); 2001; 31(1):45-50. PubMed ID: 11345403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.